Impact of Alternate Day Fasting During Chemotherapy After Surgery for Women with Uterine and Ovarian Cancer

What this Trial Is About

Endometrial cancer is the most common gynecologic cancer in women, and ovarian cancer is one of the deadliest. Both advanced uterine and ovarian cancers are usually treated with a combination of surgery and chemotherapy. Standard chemotherapy treatments, such as carboplatin and paclitaxel, can cause severe side effects that greatly affect patients quality of life. This research aims to study the impact of alternate day fasting on reducing chemotherapy side effects and improving quality of life for women undergoing first-line treatment for these cancers. Participants will be assigned to one of two groups the FAST intervention group or a control group. The FAST group will follow a modified alternate day fasting schedule during chemotherapy cycles, fasting for two consecutive days around chemotherapy administration and eating normally on other days, for a total of six weeks. The control group will eat as usual without dietary restrictions throughout their chemotherapy treatment. The study focuses on short-term fasting to minimize weight loss while potentially reducing toxic side effects. During the 18-week study period, participants will be monitored for their compliance with the fasting and treatment plans, side effects, neuropathic pain, and physical function. Surveys will be completed online, and participants will use smartphones to assist with data collection. Researchers will evaluate how well participants adhere to the regimen and record any adverse events or toxicity. This study will help inform future research on dietary interventions during chemotherapy for gynecologic cancers.

Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy